Zenosense Inc. (ZENO) Virus Detection Devices to b
Post# of 53
Posted On: 04/29/2015 8:24:01 PM
Zenosense Inc. (ZENO) Virus Detection Devices to be Time, Money and Life Savers
Methicillin-resistant Staphylococcus aureus (MRSA) is a resistant form of bacteria that stakes an infamous claim to causing infection in a variety of areas on the human body. Commonly, MRSA manifests itself in the form of boils, sores or abscesses. The MRSA bacteria is unique among staph infections because it is resistant to today’s pervasively prescribed forms of antibiotics. MRSA skin infections occupy an extenuating range from elementary to life-threatening. Due to being knowns as unpredictable and difficult to treat, MRSA is widely referred to in clinical circles as a “Superbug.”
MRSA in the form of skin rashes spreads through the resistant bacteria entering the body. While staph is common, it can cause infection when it gets into the blood via cut in the skin. This form of bacteria has evolved through generations as cultures have over prescribed and subsequently overused antibiotics to treat common colds, viruses and influenza (the flu). Even when antibiotics are appropriately used to treat bacterial infections, they cause bacteria to adjust, making them more resistant. With the MRSA constantly changing, it complicates the task for researchers to develop antibiotics that will effectively fight it.
The symptoms of MRSA found on the skin are commonly red and swollen. These infections can also look like pimples or spider bites and are pus-filled. Left untreated, infection can spread to the blood. As the infected blood moves through the body, infection of the joints, bones, heart valves and lungs can occur and result in organ failure. Other symptoms come in the form of chills, fever and cough. Patients with weak immune systems, those who live and work in care centers, such as day care centers, jails, and retirement homes are at particular risk.
Zenosense Inc. (OTCQB: ZENO) holds an exclusive global license agreement for developing and marketing medical devices within hospitals and primary healthcare facilities. The company’s devices target the early detection of both deadly bacteria like MRSA and some cancers through detection within a person’s breath. Two devices are currently being developed. One is a device intended to detect the MRSA “Super-Bug” and the other is intended to detect Lung Cancer. Through the commonly used Electronic Nose technology platform, the ZENO devices are being designed to detect volatile organic compounds (VOC’s) present in the exhaled breath of patients.
Company experts in the fields of nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are currently engaged in work necessary for product development.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Methicillin-resistant Staphylococcus aureus (MRSA) is a resistant form of bacteria that stakes an infamous claim to causing infection in a variety of areas on the human body. Commonly, MRSA manifests itself in the form of boils, sores or abscesses. The MRSA bacteria is unique among staph infections because it is resistant to today’s pervasively prescribed forms of antibiotics. MRSA skin infections occupy an extenuating range from elementary to life-threatening. Due to being knowns as unpredictable and difficult to treat, MRSA is widely referred to in clinical circles as a “Superbug.”
MRSA in the form of skin rashes spreads through the resistant bacteria entering the body. While staph is common, it can cause infection when it gets into the blood via cut in the skin. This form of bacteria has evolved through generations as cultures have over prescribed and subsequently overused antibiotics to treat common colds, viruses and influenza (the flu). Even when antibiotics are appropriately used to treat bacterial infections, they cause bacteria to adjust, making them more resistant. With the MRSA constantly changing, it complicates the task for researchers to develop antibiotics that will effectively fight it.
The symptoms of MRSA found on the skin are commonly red and swollen. These infections can also look like pimples or spider bites and are pus-filled. Left untreated, infection can spread to the blood. As the infected blood moves through the body, infection of the joints, bones, heart valves and lungs can occur and result in organ failure. Other symptoms come in the form of chills, fever and cough. Patients with weak immune systems, those who live and work in care centers, such as day care centers, jails, and retirement homes are at particular risk.
Zenosense Inc. (OTCQB: ZENO) holds an exclusive global license agreement for developing and marketing medical devices within hospitals and primary healthcare facilities. The company’s devices target the early detection of both deadly bacteria like MRSA and some cancers through detection within a person’s breath. Two devices are currently being developed. One is a device intended to detect the MRSA “Super-Bug” and the other is intended to detect Lung Cancer. Through the commonly used Electronic Nose technology platform, the ZENO devices are being designed to detect volatile organic compounds (VOC’s) present in the exhaled breath of patients.
Company experts in the fields of nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are currently engaged in work necessary for product development.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)